When profit prescribes: rethinking health through commercial determinants

Medical school teaches you that health depends on nutrition, sanitation, education, occupation, housing and income. It trains you to identify microbes, interpret laboratory values and advise lifestyle modification. It also teaches you about the social determinants of health and how poverty, housing and education shape disease patterns. Yet no one explicitly trains you to ask who designs the marketplace that surrounds these determinants. Who structures the food supply, the labour contract, the advertising environment, the digital space, and even the regulatory framework? We now understand that many risks we call “lifestyle” are embedded in systems built for commercial gain. This insight leads to a broader lens that public health has only recently begun to articulate clearly.

Health and its determinants

The World Health Organization defines health as a state of complete physical, mental and social well-being, and not merely the absence of disease. Determinants of health are conditions that influence this state. Traditionally, these are termed social determinants: income, housing, education, employment, gender relations, social protection and access to services. These determinants explain inequality and are well established in medical curricula. They emerged historically from observations that disease clusters in environments of poor sanitation and insecure labour and in deprived communities. Social determinants remain valid, but they often describe the condition without interrogating who shapes that condition in modern economies.

In the early 2010s, scholars began speaking about the corporate determinants of health, later broadened to commercial determinants of health, to capture a wider set of market actors. The term gained visibility in academic circles around 2013 and has since been developed through global commissions and policy reports. The idea recognises that commercial actors influence health not only through products, but through systems and power structures. Despite this conceptual growth, policy translation remains limited, and most medical education continues to foreground social determinants while ignoring commercial influence as a determinant. The shift in terminology reflects a recognition, however, that organised market systems now shape determinants at scale.

What do commercial determinants mean

Commercial determinants of health refer to systems, practices and pathways through which commercial actors drive health and equity outcomes. The central argument is not that commerce is inherently harmful, but that current political and economic arrangements often prioritise profit maximisation over population well-being. Since the late twentieth century, globalisation, deregulation, privatisation and financial concentration have expanded corporate power. In such a system, firms can influence regulation, research agendas, public narratives and labour structures. The result is a structural imbalance in which commercial incentives shape the environments in which people live, work, and consume, often faster than public institutions can respond.

The burden of harm

A substantial share of preventable non-communicable diseases is linked to commercial sectors such as tobacco, alcohol, ultra-processed foods and fossil fuels. These industries have historically shaped policy debates and consumer norms, while health systems manage downstream consequences. Today, the arena is broader. App-based food delivery models combine convenience with labour precarity and altered dietary patterns. Digital platforms create infinite content streams that monetise attention through advertising, gambling prompts, vaping imagery and pornography. Devices are engineered for prolonged engagement. In each case, profit is recorded privately while the impact of these results in chronic disease, injury, addiction and mental distress that generates costs borne by families and public systems.

The commercial determinants framework identifies several interacting mechanisms. Political practices include lobbying and regulatory negotiation. Scientific practices involve funding and framing evidence. Marketing practices shape norms and consumer desire. Labour practices can externalise occupational risk. Financial strategies can reduce public revenue through tax structures. Reputational management positions firms as partners in health even when incentives remain misaligned. These practices operate within broader political and economic systems characterised by concentrated wealth and power. Externalities become central: costs of harm are shifted away from firms and absorbed by society. Over time, this feedback loop reinforces inequality and weakens regulatory capacity.

Why it matters

This framework matters because it reframes disease as a structural outcome rather than solely an individual failure. When economic power concentrates and commercial actors shape policy and information, social determinants are reshaped in turn. Food environments, work patterns, energy systems and digital ecosystems become commercial products. In the 21^st century, where the legally accumulated global wealth is at a historic peak for humanity, yet preventable diseases remain high, the explanation must extend beyond poverty alone. Understanding commercial determinants equips clinicians and policymakers to recognise how markets design risk. Without this perspective, public health remains reactive, treating diabetes, addiction and injury without examining the systems that make them.

Invisible data

The Global Burden of Disease 2019 analyses indicate that four industries in particular, tobacco, alcohol, ultra-processed food production and fossil fuel extraction, are linked to a substantial share of non-communicable diseases worldwide, together accounting for close to one-third of the burden and contributing to an estimated 19 million deaths annually through cancers, cardiovascular disease, chronic respiratory disease and metabolic disorders. Yet even this estimate may understate reality. Health surveillance systems are designed to record diseases, not the commercial architectures that shape exposure. Marketing intensity, political lobbying, labour precarity and supply chain practices are rarely captured in routine datasets. As a result, attribution remains indirect and fragmented. The commercial actor often appears several steps removed from the clinical outcome, making systematic measurement and accountability difficult.

Rebalancing health and commerce

Commerce contributes to health through innovation, pharmaceuticals, logistics and technology. The objective is not to reject markets but to realign them. Solutions lie in strengthening regulatory capacity, improving transparency around political and scientific influence, addressing labour protections, ensuring fair taxation, and embedding health impact assessment into economic policy. Medical education should integrate commercial determinants alongside social determinants, to prepare future clinicians for structural analysis.

A rebalanced system would reduce externalised harm, distribute benefits more equitably and ensure that economic growth does not prescribe disease. When incentives align with well-being, profit, and public health, they need not stand in opposition.

(Dr. C. Aravinda is an academic and public health physician. The views expressed are personal. aravindaaiimsjr10@hotmail.com)

Published – March 03, 2026 07:25 pm IST